GlassScriptPhysician profile
Charles K Newell
NPI 1245298223
$29,570.45
in general payments reported to CMS, 2019-2025
16 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,140 · 2020: $2,931 · 2021: $12K · 2022: $9,497 · 2023: $243 · 2024: $224 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $28,153.53 | 2019-2022 | |
| Genentech USA, INC. | $306.21 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $170.64 | 2022-2024 | Eylea Hd, Eylea |
| Genentech, INC. | $154.33 | 2019 | |
| Harrow Eye, LLC | $145.97 | 2025 | Triesence |
| Apellis Pharmaceuticals, INC. | $138.48 | 2023-2025 | Syfovre |
| Allergan, INC. | $92.73 | 2019-2021 | |
| Abbvie INC. | $82.11 | 2022-2023 | |
| Astellas Pharma US INC | $71.14 | 2023-2025 | Izervay |
| Dendreon Pharmaceuticals LLC | $60.37 | 2019-2025 | Provenge |
| Alcon Vision LLC | $59.03 | 2022-2025 | Precision7 |
| Bausch & Lomb Americas INC. | $39.67 | 2023-2024 | Ic-8 Apthera Iol, Xipere |
| Novartis Pharmaceuticals Corporation | $27.28 | 2019 | |
| Sandoz INC. | $26.38 | 2024 | Cimerli |
| Olympus America INC. | $22.52 | 2025 | Itind System |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $20.06 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$780,218.40 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Newell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.